Join
Live feed
·
PRReleasevia Quantisnow
Connect Biopharma Holdings Limited logo

Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

ByQuantisnow·Wall Street's wire, on your screen.
CNTB· Connect Biopharma Holdings Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CNTB (Connect Biopharma Holdings Limited) and more on Quantisnow.